A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or death. Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease.In this 12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who...